- Home
- TRUG vs SABS Comparison
TRUG vs SABS Comparison
Compare TRUG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- SABS
- Stock Information
- Founded
- TRUG 1983
- SABS 2014
- Country
- TRUG United States
- SABS United States
- Employees
- TRUG N/A
- SABS N/A
- Industry
- TRUG
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- SABS Health Care
- Exchange
- TRUG NYSE
- SABS Nasdaq
- Market Cap
- TRUG 16.2M
- SABS 19.0M
- IPO Year
- TRUG N/A
- SABS N/A
- Fundamental
- Price
- TRUG $0.47
- SABS $1.82
- Analyst Decision
- TRUG Strong Buy
- SABS Strong Buy
- Analyst Count
- TRUG 1
- SABS 5
- Target Price
- TRUG $2.00
- SABS $12.40
- AVG Volume (30 Days)
- TRUG 5.4M
- SABS 246.2K
- Earning Date
- TRUG 03-04-2025
- SABS 03-28-2025
- Dividend Yield
- TRUG N/A
- SABS N/A
- EPS Growth
- TRUG N/A
- SABS N/A
- EPS
- TRUG N/A
- SABS N/A
- Revenue
- TRUG $21,917,131.00
- SABS $1,512,723.00
- Revenue This Year
- TRUG $11.00
- SABS N/A
- Revenue Next Year
- TRUG $20.54
- SABS N/A
- P/E Ratio
- TRUG N/A
- SABS N/A
- Revenue Growth
- TRUG 7.68
- SABS N/A
- 52 Week Low
- TRUG $0.35
- SABS $1.60
- 52 Week High
- TRUG $2.27
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- TRUG 48.97
- SABS 36.28
- Support Level
- TRUG $0.36
- SABS $2.00
- Resistance Level
- TRUG $0.67
- SABS $2.15
- Average True Range (ATR)
- TRUG 0.05
- SABS 0.20
- MACD
- TRUG 0.01
- SABS 0.03
- Stochastic Oscillator
- TRUG 31.69
- SABS 30.99
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.